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Abstract
The immune system can be a cure or cause of disease, fulfilling a protective role in attacking
cancer or pathogenic microbes but also causing tissue destruction in autoimmune disorders. Thus,
therapies aimed to amplify or suppress immune reactions are of great interest. However, the
complex regulation of the immune system, coupled with the potential systemic side effects
associated with traditional systemic drug therapies, has presented a major hurdle for the
development of successful immunotherapies,. Recent progress in the design of synthetic micro-
and nano-particles that can target drugs, deliver imaging agents, or stimulate immune cells directly
through their physical and chemical properties is leading to new approaches to deliver vaccines,
promote immune responses against tumors, and suppress autoimmunity. In addition, novel
strategies, such as the use of particle-laden immune cells as living targeting agents for drugs, are
providing exciting new approaches for immunotherapy. This progress report describes recent
advances in the design of micro- and nano-particles in immunotherapies and diagnostics.
1. Introduction
The immune system is a distributed network of cells and lymphoid organs, which play a
critical role in providing protection from infectious microbes, and perhaps also in restraining
the development of tumors.[1] It is comprised at the organ level of secondary lymphoid
organs, including the spleen, nasal-associated lymphoid tissue, Peyer’s patches in the gut,
and lymph nodes distributed throughout the body. (Primary lymphoid organs, the thymus
and bone marrow, are sites where immune cells are generated from stem cells throughout
life). At the cellular level, the key components are innate and adaptive immune cells. Innate
cells such as macrophages, neutrophils, and natural killer cells provide immediate defense
against infections at portals of entry such as mucosal surfaces and the skin.[2,3] By contrast,
adaptive immune cells (T-cells and B-cells) reside in lymphoid organs or tissues and are
slower to respond to infectious challenges, but can differentiate into long-lived memory cells
that provide rapid protection on re-exposure to pathogens.[4]
Manipulation of the immune system by therapeutic interventions is of great interest due to
the pervasive role of immunity in health and disease. In many instances, we seek to induce
or amplify the normal functions of the immune system. One of the most successful
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biomedical interventions ever devised, vaccination, relies on stimulating immune memory to
protect immunized individuals from future encounters with dangerous microbes.[1]
However, effective vaccines are still elusive for a number of important infectious pathogens,
such as HIV, malaria, tuberculosis, and hepatitis C. Cancer immunotherapies are treatments
aiming to stimulate a patient’s immune system to attack and destroy tumors, usually in the
presence of pre-existing disease; recent successes suggest much promise in this field[5–7] but
cancer remains a major challenge in medicine. On the other hand, the immune system can
also cause disease itself if immune cells attack healthy tissue (autoimmunity); in this case,
therapeutic interventions to restrain immune responses are sought.[8] In addition to
therapeutic modulation, there is also a need for strategies to monitor and measure immunity.
The disseminated nature of the immune system has made clinical analysis and monitoring of
immune function a major challenge, and improved methodologies to track and diagnose the
function of the immune system are desperately needed.
Micro- and nano-scale synthetic particles have a major role to play in solving these
problems. The complexity of signals regulating proper functioning of the immune system
creates a major challenge for therapies based on traditional single-agent bolus drug
treatments. Engineered particles are being intensively studied as delivery vehicles and
adjuvants for vaccines,[9–12] components of diagnostic systems to analyze ongoing immune
responses and immune cell trafficking in vivo,[13,14] as systems for the ex vivo expansion of
therapeutic immune cells for treatment of cancer and infectious diseases,[6,15,16] and as
delivery agents for immunotherapy drugs.[17–20] Nanoparticles (NPs) and microparticles
(MPs) tailored for these applications are enabling new means to detect and treat diverse
conditions with major implications for global health, ranging from cancer to infectious
disease to autoimmune disorders. In this progress report, we will summarize recent advances
in the design and implementation of engineered particles that can sense, stimulate, or
suppress immune reactions by interactions with single cells or with whole tissues/organs,
and highlight challenges for which new materials are needed. An exhaustive overview of
this rapidly expanding field is beyond the scope of any single review, and we thus aim to
highlight areas where particle technologies are already having impact or where new
approaches in nano/micro-particle design are ripe for application to problems in tuning or
taming the immune system.
2. Shaping immune reactions at the single-cell level: tailoring particle
interactions with leukocytes
Cell-cell communication by direct contact and engagement of membrane receptors plays a
major role in regulating the functions of immune cells. Perhaps the most important cell-cell
interaction in the induction of adaptive immune responses occurs during the activation of T-
cells by specialized, rare antigen presenting cells (APCs) known as dendritic cells (DCs).[21]
Synthetic particles can be designed to display receptors and co-stimulatory ligands normally
expressed on the surface of DCs, thereby mimicking activated APCs and inducing T-cell
activation and differentiation. This strategy can be applied in adoptive cell therapies and
vaccine development, where engineered synthetic particles may replace APCs and directly
interact with T cells to regulate their differentiation and effector functions. Another
important aspect in the use of particles as drug delivery agents is the interaction between
particles and phagocytic cells, such as macrophages. By modulating particle size, shape, and
elastic properties, particle uptake by phagocytes can be tailored at the single-cell or whole
organ level, providing the means to optimize drug delivery to particular tissues and organs.
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2.1 Synthetic particles as artificial antigen presenting cells
The organized contact between a T-cell and dendritic cell during T-cell activation is known
as an immunological synapse (Fig. 1A).[21] DCs have the task of capturing fragments of
pathogens from the environment (or from dying infected cells) and physically displaying
peptides of foreign material (antigen) to T-cells in the cleft of surface receptors known as the
Major Histocompatibility complex (MHC) molecules.[22] Every T-cell expresses a unique T-
cell receptor (TCR) and when T-cells contact a DC displaying a cognate antigen, T-cell
activation occurs, mediated by the assembly of receptors and secreted factors at the T-APC
interface (the synapse). Dendritic cells play a critical role in instructing T-cells to mount the
appropriate immune response needed for a particular microbial invader, via the type of co-
stimulatory ligands they present to the T-cell and soluble cytokines released at the synapse,
which determine the effector functions of the responding T-cell (Fig. 1A).
This crucial role played by DCs in the adaptive immune response has motivated the design
of microparticles that can mimic the function of these cells in contact-mediated
programming of T-cells, providing a convenient strategy to artificially stimulate T-cell
activation in vitro or in vivo (Fig. 1B). Stimulation of the TCR by surface-anchored antigen/
MHC complexes (or antibodies that mimic these natural ligands) rather than soluble ligands
is required to properly activate T-cells, and so the simplest forms of MP-based “artificial
APCs” (aAPCs) are monodisperse cell-sized polystyrene beads conjugated with
immobilized peptide-MHC and costimulatory receptor ligands; such simple DC surrogates
are now a common tool in immunology,[15,23,24] and are used in clinical procedures such as
adoptive cell therapy, where autologous tumor-specific T-cells are activated and expanded
by stimulatory MPs in cell culture prior to infusion into patients to combat cancer.[15,25,26]
More recently, particle engineering has been used to design multifunctional aAPCs that are
endowed with more of the physiological features of genuine antigen presenting cells. For
example, aAPCs composed of biodegradable poly(lactide-co-glycolide) (PLGA) micro- or
nano-particles surface-modified with avidin-palmitate conjugates have been generated to
anchor peptide-MHC and costimulatory ligands to the particle surfaces (Fig. 1B).[16]
Interestingly, when incubated with lymphocytes, ligand-displaying MPs 8 μm in diameter
(mimicking APCs in size) stimulated much greater total T-cell activation than NPs (130 nm
diameter) displaying the same activation signals.[16] This result might reflect internalization
of NPs by T-cells,[27] leading to particle degradation and early termination of TCR
signaling. By contrast, T-cells formed stable, tight synapse-like contacts with ligand-
displaying microparticles (Fig. 1B). To further mimic cytokine production by DCs
themselves[28,29] or helper T-cells in the local microenvironment in vivo, aAPCs were
loaded with the key T-cell growth factor interleukin-2 (IL-2), which was released over ~1
week in culture. [16] Cytokine-releasing aAPCs stimulated T-cells more strongly than
commercial MPs or PLGA particles displaying TCR ligands and costimulatory ligands
alone. Interestingly, T-cell expansion stimulated by IL-2-releasing aAPCs was greater than
that achieved when T-cells were co-cultured with aAPCs lacking encapsulated cytokine but
supplemented with a 10-fold greater total soluble dose of IL-2 added to the medium.[16] This
result may be due to the local concentration of the cytokine and IL-2 receptors in the
synapse formed between the T-cell and synthetic particle,[30] as IL-2 delivered in a paracrine
manner is very efficiently consumed by T-cells[31] and modeling of the T-cell/aAPC
interface suggested that the concentration of IL-2 developing in the synapse near an IL-2-
releasing particle exceeds that obtained with a 1000-fold-greater concentration of cytokine
added to the bulk solution.[16] Furthermore, it was shown that the potent response of T-cells
to particle-released IL-2 was dependent on sustained release of the growth factor over
time.[16,32]
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In addition to their use for expanding T-cells in vitro, polystyrene MPs displaying T-cell-
activating ligands have also been employed to prime T-cell responses directly in vivo with
the goal of avoiding costly and laborious ex vivo culture procedures.[33,34] Particles
prepared from fully biodegradable materials such as the PLGA particles described above
will have obvious advantages for translation of such in vivo immunostimulation approaches
to clinical use. A potentially interesting area for future design of particles that serve as
surrogates of APCs is the design of particles that mimic the physical organization of the
“mature” immunological synapse. The mature synapse is characterized by a central cluster
of TCRs and signaling proteins, surrounded by a peripheral ring enriched in accessory
molecules and adhesion receptors (Fig. 1A).[21] Methods developed for the creation of so-
called Janus particles[35–37] may be relevant for mimicking this arrangement– for example,
patchy anisotropic particles displaying micron-scale patches of one protein surrounded by a
second component were synthesized by masking contact points of particles in a colloidal
crystal in a reversible manner, followed by modification with proteins (Fig. 1C).[38]
Strategies to provide fixed structures mimicking the mature synapse might also be
supplemented by the use of particles displaying synapse proteins on MPs coated with fluid
lipid membranes,[39] thereby allowing self-reorganization of receptors and signaling
molecules during the interaction with T-cells. Such approaches utilizing increasingly refined
particle designs may provide the means to tune the differentiation state of T-cells by more
closely mimicking the interaction of T-cells with native APCs.
2.2 Engineering particle interactions with phagocytes
2.2.1 Role of particle shape—Much effort has focused on determining how the
properties of synthetic MPs and NPs influence binding and internalization by macrophages
in the spleen and liver, since this clearance hinders systemic delivery of therapeutics or
diagnostic/imaging agents by particles. Early efforts to design phagocytosis-resistant
particles focused on engineering surface chemistry to block protein adsorption and
complement interactions with the particle surface (a process known as opsonization), since
such adsorbed/bound serum components serve as a molecular handhold for phagocyte
binding and internalization. The most widely employed strategy for limiting opsonization is
to introduce a dense layer of anchored poly(ethylene glycol) (PEG) at the particle surface,
which sterically resists protein interactions with the particle.[40,41] Certain zwitterionic
polymers can also be used for particle surface modification to achieve even better protection
of particles from opsonization via tight water binding at the particle/solution interface.[42]
Recently, it has become evident that surface chemistry is not the only property to play a
significant role in dictating the interactions of particles with phagocytes– particle
mechanical properties and geometrical shape also have a major influence on the outcome.
The latter property has only become clear in the last few years with the advent of powerful
new particle fabrication methodologies.[43–46] Using plastic deformation of polymer
microspheres and nanospheres embedded in a sacrificial matrix to fabricate MPs and NPs of
diverse geometries, it was shown that while spherical particles are readily internalized,
highly anisotropic MPs are very poorly phagocytosed along their length by macrophages in
vitro, due to incomplete formation of actin rings that circumscribe the initial contact point
during phagocytosis (Fig. 2A).[47] Needle-shaped polymer particles with aspect ratios of ~10
and a narrow dimension of ~0.5 μm were also found to promote transient (non-toxic)
permeabilization of cell membranes,[48] further emphasizing the interplay between particle
shape and cellular responses. Particle internalization responses appear also to be size- and/or
cell type-dependent, as a recent study reported that internalization of monodisperse PEG
hydrogel nanoparticles by transformed epithelial HeLa cells was much more efficient for
rod-like, high-aspect-ratio NPs, compared to cylindrical counterparts with similar
volume.[49] These contrasting results may stem from different phagocytic/endocytic
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pathways triggered by particles of micron vs. submicron size, or distinct uptake pathways
employed by professional phagocytes vs. other cell types. Exploiting the fact that
phagocytosis of highly anisotopic microparticles is frustrated if the “wide” face of the
particle contacts a macrophage, Doshi et al. fabricated polyelectrolyte multilayer polymer
discs 4–7 μm in diameter but less than a micron in thickness with a cell-binding hyaluronic
acid surface layer on the face of each disc;[50] when mixed with macrophages, these disc-
shaped “backpacks” bound to the cells via the flat face of the disc, a configuration allowing
strong adhesion to the cells but no internalization of the discs by the phagocyte.[19] By
loading the polymer multilayers with relevant therapeutics, macrophages might be exploited
as cellular chaperones to carry drug-loaded backpacks to disease sites from the circulation,
such as tumors, infection sites, or lymphoid organs (discussed further below).
Does shape influence the fate of particles in vivo? When a series of model PS particles
coated with anti-ICAM-1 antibodies to target binding to endothelial cells (ECs) were
compared, disc-shaped particles with a narrow dimension of 0.1 μm and diameter of 3 μm
achieved lower liver uptake, higher lung accumulation (where a large fraction of ECs are
located in the pulmonary vasculature), and greater antibody-specific vasculature binding.[51]
In relative agreement with these findings, uncoated silica particles of varying geometries
(spherical, discoidal, or cylindrical) but nearly identical volumes prepared using lithography
showed that discs accumulated to a lower degree in the liver but more in the lungs compared
to spheres.[52] By contrast, cylindrical particles showed greater uptake in the liver than either
of the other two particle shapes for this particular size. In vitro flow chamber studies and
computational modeling have suggested that discoidal particles with large contact area with
cell membranes pose a significant barrier for phagocytes to polymerize sufficient actin to
wrap around particles and “frustrate” the internalization process, thereby evading
internalization by the Kupffer cells in the liver and increasing delivery to other organs.[53–56]
In contrast, more symmetric spherical and cylindrical particles with a smaller contact area
with cell membranes tended to be internalized by Kupffer cells. Finally, studies of
irregularly-shaped ~350 nm diam. poly(maleic anhydride)/lipid composite particles showed
preferential uptake in the spleen when compared to spherical particles of similar
composition and size, which instead showed predominant uptake in the liver.[57] A key
aspect of this latter study of splenic particle tropism was the recognition that the murine
spleen lacks the sinusoidal structure shared by the spleen of humans, rats, rabbits, and dogs,
and thus the analysis was carried out in the latter 3 animal models where the splenic
endothelium architecture more closely approximates that of humans. Altogether, these
studies suggest that particle shape may be as important as surface chemistry in the design of
particles designed to avoid (or target) liver and splenic macrophages.
2.2.2 Role of particle mechanical properties—Red blood cells (RBCs) have been
considered as ideal models for designing long-circulating synthetic particles, since the
lifetime of RBCs in humans is ~120 days.[58–60] To match the surface chemical composition
of RBCs, PLGA NPs were extruded with mouse RBC-derived membranes to coat the former
with RBC lipids and proteins.[61] The RBC shell on the NPs greatly increased the in vivo
circulation half-life of these synthetic particles to 40 h, compared to 16 h for identical
particles functionalized with PEG, or bare particles that aggregated in blood immediately.
This result suggests that the ability of RBCs to evade the reticuloendothelial system (RES) is
partially due to molecular moieties on the RBC surface, such as the cellular recognition
protein CD47, which has been shown to inhibit phagocytosis when bound on particle
surfaces[62] by providing a “don’t-eat-me” signal for macrophages.[63] However, cell shape
and mechanical properties also play an important role in the long in vivo half-life of natural
RBCs. In vitro mechanical measurements have revealed that RBCs lose their deformability
as they age, due to shrinking surface area and stiffening membranes.[64,65] It is also known
that opsonized rigid particles are preferentially phagocytosed by macrophages over soft
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particles by stimulating actin filament assembly required for phagocytosis.[66] Notably, the
discoid particles discussed above exhibiting reduced phagocytosis in the liver are
reminiscent of RBCs in shape. With these considerations in mind, several groups have
actively aimed to produce particles that can mimic the size, shape, and modulus of RBCs to
prolong their in vivo persistence.
To investigate whether RBC geometry and mechanical properties could be copied to
enhance the circulation times of synthetic particles, Mitragotri and colleagues designed
polymer MPs with biconcave geometry, which mimicked the key structural and functional
features of live mouse RBCs.[67] Polymeric cores were used as a template, upon which
layer-by-layer polymer coatings containing drug cargos were applied, followed by chemical
crosslinking to stabilize the shell. Dissolution of the template core yielded hollow
microcapsules mimicking the size, shape, and elastic modulus of RBCs. These synthetic
RBCs could deform and flow through capillaries smaller than their resting diameter,
suggesting that these materials may enhance sustained systemic delivery of therapeutics and
diagnostic agents in vivo. The authors demonstrated three preliminary examples: surface-
adsorbed hemoglobin for oxygen delivery, encapsulated iron oxide nanocrystals as imaging
contrast agents, and encapsulated heparin as an anti-coagulant. Finally, to study the
importance of elastic modulus in RBC circulation, Merkel et al. used lithographic particle
fabrication to generate 2-hydroxyethyl acrylate hydrogel particles with tunable stiffness
based on crosslinking density, achieving a range of modulus from ~8 to 64 kPa, which spans
the reported modulus for RBCs of 26 ± 7 kPa.[68] These swollen hydrogels particles were
also designed with a biconcave geometry and approximate dimensions of RBCs, and
exhibited low toxicity and endocytosis by cells in vitro. When circulated in 3 μm wide
microfluidic channels, softer lightly-crosslinked particles were able to deform and pass
through repeatedly, while stiffer particles clogged. In vivo pharmacokinetics analysis
revealed that particles with the lowest elastic modulus had circulation half-lives of 3.6 days
with significant accumulation in the spleen, whereas rigid particles of similar shape were
rapidly trapped in the lungs after injection.
A final important recent example of the impact of combined shape and elasticity engineering
on particle-phagocyte interactions comes from a study by Geng et al. examining cylindrical
block micelles.[69] Highly anisotropic flexible filomicelles assembled from block
copolymers several microns in length (with micellar diam. < 100 nm) exhibited greatly
reduced uptake by macrophages, compared to spherical micelles of the same materials. In
conditions mimicking blood flow relevant to systemic therapeutic delivery, these cylindrical
particles aligned their long axis with the flow. When the flow-aligned end of a filomicelle
made an adhesive contact with the surface of a macrophage, fluid flow provided a shear
force on the flexible shaft of the particle sufficient to break the adhesive contact with the cell
prior to internalization (Fig. 2B). These experiments highlight the importance of considering
particle-cell interactions in the context of the local microenvironment where these
interactions will occur (in this case, in blood flow passing through the spleen or liver). When
injected intravenously, PEO-PCL filomicelles exhibited increasing circulation time as a
function of initial length up to approximately 8 μm, with a fraction of particles persisting in
blood even after one week,[69] and this led to improved accumulation of the chemotherapy
drug paclitaxel in xenograft lung tumors.[69,70]
3. Nano- and micro-particle vaccines
3.1 Arming and activating antigen presenting cells
Much effort in modern vaccine development has revolved around the design of subunit
vaccines, comprised of purified components of pathogens (antigens) to elicit a focused
immune response without the dangers associated with live attenuated pathogens. However,
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purified subunit antigens are poorly immunogenic, and require formulation with adjuvants,
substances that promote the immune response.[71] Synthetic particles packaging antigen and
immunostimulatory molecules are of great interest for next-generation subunit vaccines, by
mimicking microbes that are themselves nanoparticles (viruses) or microparticles (bacteria),
without the complications of toxicity and anti-vector immune responses that are often
elicited by recombinant viral/bacterial vaccines.[72] APCs are the primary target of particle
vaccines due to their ability to initiate and sustain both cellular and humoral immune
responses. In particular, dendritic cells are canonically considered the most potent activators
of naïve T cells,[73] although recent studies have suggested that macrophages can also play
an important role in T-cell priming by particle vaccines.[74] DCs internalizing particulate
immunogens are triggered to process antigens for loading onto class I MHC molecules in a
process known as cross-presentation (to prime CD8+ T-cells, important for viral and cancer
vaccines).[75,76] In addition, effective crosslinking of B-cell receptors via multivalent
display of antigen on particle surfaces can promote the humoral response.[77,78] Particle
vaccines are typically injected subcutaneously or intradermally, and subsequently drain
through lymphatics to DCs in lymph nodes or are internalized by DCs directly at the
injection site. To mount an effective immune response, vaccine particles acquired by APCs
must effectively release their antigen cargo and activate these cells to trigger subsequent
antigen presentation and T-cell priming.
3.1.1 Engineering synthetic particles for intracellular delivery of antigen—Once
antigen-carrying vaccine particles are internalized by DCs or other APCs, the antigen must
be released for proteolysis and loading on MHC molecules. Studies of the kinetics of antigen
processing in DCs have suggested that following internalization of particle-associated
antigens into the phagosomal/endolysosomal pathway, there is a relatively narrow window
of time when antigens are productively processed for loading onto MHC molecules before
they are fully degraded.[79] Thus, particles have been designed to rapidly release antigen
following internalization: Antigen delivery to DCs using acetylated dextran NPs that
undergo rapid breakdown at mildly acidic pH characteristic of early endosomes/phagosomes
significantly enhanced MHC I presentation of antigen in vitro, compared to NPs with slower
degradation profiles, demonstrating that the intracellular antigen release rate can be tuned
precisely with vaccine particles to promote antigen presentation.[80] A second strategy to
enhance antigen processing from vaccine particles is to take advantage of the reducing
environment within endosomes for selective antigen release. For example, peptide- and
protein-loaded redox-sensitive polymer microcapsules have been prepared by layer-by-layer
assembly onto a sacrificial colloidal core, followed by dissolution of the core template. The
resulting hollow capsules are stabilized by disulfide linkages that are cleaved in
endolysosomes (Fig. 3A).[81,82] Antigens have also been linked to the surfaces of NP
carriers by reduction-sensitive disulfide linkages for rapid intracellular release.[83,84] A third
approach is to design particles capable of disrupting endosomes to transport antigens
directly into the cytosol, where class I MHC antigen processing is normally initiated. This
can be achieved by polymer particles containing pH-buffering units that induce an osmotic
pressure buildup and disrupt endosomes, a strategy commonly employed in gene
delivery.[85] Exploiting this mechanism, particles composed of pH-responsive
poly(diethylaminoethyl methacrylate)[86] have been synthesized to enhance the ability of
DCs to cross-present particle-bound protein antigens to CD8+ T-cells. Endosome-escaping
particles can also be used to deliver mRNA or DNA encoding antigens into APCs.[87]
Another physicochemical strategy demonstrated for vaccine delivery to the cytosol uses
particles incorporating weak polyacids, which are hydrophilic and water-soluble at neutral
pH but become hydrophobic and membrane-lytic when the acid groups are protonated at
acidic pH.[88,89] These endosome-disrupting antigen delivery strategies may have additional
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adjuvant effects, since disruption of endolysosomes in APCs has been suggested to activate
intracellular danger sensors known as inflammasomes that promote DC activation. [90]
3.1.2 Engineering APC activation with particles carrying molecular adjuvants
—Natural pathogens are particulate packages of antigens and “danger signals”, which
trigger APCs to elicit appropriate immune responses and deal with the detected threat (e.g.,
bacteria, virus, fungus). During natural infection, these activation cues are derived from
conserved molecular motifs characteristic of pathogens, such as lipopolysaccharide (a
signature of Gram-negative bacteria), unmethylated C-G oligonucleotide sequences
(characteristic of bacterial DNA), or single-stranded RNA molecules (characteristic of viral
genomes).[91] Activation signals can also be derived from factors associated with tissue
stress, such as extracellular DNA-binding proteins (signatures of cell death) or fragmented
extracellular matrix polysaccharides (signatures of tissue damage).[92] APCs express cell
surface and intracellular receptors to sense these “danger signals.” Particularly prominent in
vaccine design are adjuvant molecules targeting the Toll-like receptor (TLR) family of
pattern-recognition receptors, a group of 10 cell surface and endolysosomal receptors, which
control sensing of a variety pathogens[91,93] and promote immune responses leading to long-
lived immunological memory.[94] When microbes are internalized by APCs, antigen and
activation signals are received simultaneously, and there is evidence that such a physical
association of antigen and activating ligands is important for maximal immune
responses.[95,96] These observations have motivated many recent studies of particle vaccines
incorporating both antigen and danger signals.
Biodegradable NPs composed of PLGA, a polymer used in multiple FDA-approved
products, have shown promise for molecular adjuvant/antigen co-delivery in a number of
studies. PLGA particles carrying antigen and either lipopolysaccharide,[97] a ligand for
TLR-4, or less toxic CpG oligonucleotides (ligands for TLR-9),[98] conferred protection on
nearly all vaccinated animals against a live challenge of West Nile virus. PLGA NPs co-
encapsulating the TLR4 agonist, MPLA, and tumor antigens activated DCs in lymph nodes
and induced anti-tumor immune responses that reduced melanoma tumor burden in vivo.[99]
As an interesting counterpoint to these studies of antigen/danger signal co-delivery, it has
also been shown that extremely potent B-cell responses accompanied by long-lived germinal
centers and durable humoral immunity can be triggered following immunization with
nanoparticle mixtures, where PLGA NPs containing TLR agonists are mixed with particles
containing antigen,[11] a finding consistent with humoral responses measured in other
studies of PLGA particle vaccines.[100–102] Understanding the distinct cellular and
molecular mechanisms invoked by particle vaccines in these two different scenarios will be
a key goal to move this field forward.
A major challenge for non-living subunit vaccines is the generation of strong CD8+ T-cell
responses, which may be required for protective vaccines against cancer or intracellular
pathogens such as HIV, hepatitis, and malaria. Current licensed adjuvants such as alum elicit
weak or non-existent CD8+ T-cell responses.[71,103] The ability of synthetic particles to
trigger “cross presentation” of exogenous antigen by DCs to CD8+ T-cells may provide a
path for effective T-cell responses to subunit antigens. Recent efforts using particles to co-
deliver antigen and TLR agonists in particular is showing for the first time potent T-cell
responses to whole protein vaccines previously only observed with recombinant viral
vectors. Nordly and colleagues emulsified the TLR-3 agonist polyI:C with the cationic
surfactant dimethyldioctadecylammonium and the immunopotentiator trehalose 6,6′-
dibehenate, generating stable gel-state multilamellar liposomes with polyI:C densely packed
between the bilayers and antigen adsorbed to the surface of the particles.[104] Immunization
with these polyI:C/antigen particles elicited impressively high frequencies of antigen-
specific IFN-γ-secreting T cells in vivo. In a second key recent study, Moon et al. stabilized
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antigen-loaded vesicles by the introduction of bilayer-to-bilayer dithiol-crosslinkers in the
walls of multilamellar lipid vesicles containing maleimide-functionalized lipids, resulting in
interbilayer-crosslinked multilamellar vesicles (ICMVs).[10] ICMV particles with the TLR-4
agonist monophosphoryl lipid A embedded throughout the vesicle walls and antigen
entrapped in the particle core elicited massive CD8+ T-cell expansion following s.c.
immunization, promoted induction of a central memory phenotype believed to enhance
recall responses, and augmented cytokine production by responding T-cells. However, as a
counterpoint to the strategy of co-delivering strong TLR agonist adjuvant molecules, a third
recent study showed that antigen-coated PLGA MPs injected intravenously in the absence of
adjuvants prime the immune system to elicit rapid and robust expansion of memory CD8+
T-cells following boosting with viral vectors or other strong booster immunizations.[10]
Together with recent clinical trial results showing enhanced survival in lung cancer patients
immunized with liposomal vaccines,[105] these data suggest there is reason to be optimistic
for the development of fully synthetic vaccines that can elicit protective T-cell responses in
humans.
Several recent studies have exploited the chemical nature of TLR ligands to enhance their
incorporation into particle vaccine systems. For example, calcium phosphate NPs are
biodegradable but also prone to aggregation, which could be avoided by adsorbing
negatively charged poly(I:C) or CpG to the outer shell of the particles. Poly(I:C)/CpG-
stabilized particles co-loaded with influenza hemagglutinin (HA) peptide were efficiently
taken up by murine splenic DCs and induced DC maturation and proliferation of HA-
specific T cells in vitro.[106] Another study used the phosphate groups on the CpG backbone
as reactive groups to crosslink N-trimethyl-chitosan and protein antigen to form a NP
vaccine that could be administered non-invasively by the intranasal route.[107] This clever
dual usage of CpG as crosslinker and adjuvant translated into serum and mucosal humoral
responses that were biased toward the potent IgG2a antibody isotype, and increased T-cell
production of IFN-γ, an important effector cytokine. Finally, pathogen-derived polymers can
be directly used to form vaccine delivery particles with built-in adjuvant activity. NPs
composed of poly(γ-glutamic acid) from bacterial capsules strongly activated and matured
DCs in vitro and produced both humoral and cellular responses when used as an antigen
carrier in vivo.[108] These particles exerted their effects through TLR-4 and its downstream
signal transducers MyD88 and MAP kinase.
In addition to TLRs, other danger signal receptors such as intracellular NOD-like receptors,
DNA and RNA sensors, and extracellular complement pathways can also be exploited to
improve the efficacy of particle vaccines. It has been recently found that PLGA particles
without any additional adjuvant can activate an intracellular stress-sensing pathway known
as the inflammasome in DCs and promote secretion of IL-1β;, IL-18, and IL-1α.[109] PLGA
particles carrying antigen and lipopolysaccharide activated both TLR-4 and inflammasomes
simultaneously, providing enhanced protection against West Nile virus compared to the
conventional adjuvant alum.[97] Activation of inflammasomes is not the only intracellular
response pathway that can be triggered by particle vaccines. DCs incubated with NPs of
αAl2O3 with surface-conjugated antigen, a nanoscale version of the canonical adjuvant
alum, promoted very strong proliferation and IL-2 secretion by CD8+ T cells in an in vitro
cross presentation assay, 10-fold higher than antigen supplemented with other danger signal
stimuli.[61] The potency of these alumina NPs was attributed to the activation of autophagy,
a cytoplasmic protein and organelle degradation pathway that also sequesters and delivers
intracellular pathogens for antigen processing, and is reciprocally regulated by TLR
signaling (Fig. 3B).[110] Particle surface chemistry can also be engineered to activate the
complement system and functionalize particles with danger signals in situ: Poly(propylene
sulfide) (PPS) NPs coated with pluronics promoted activation of complement on contact
with serum, promoted by the hydroxyl endgroups of the pluronic stabilizer. These
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complement-activating particles elicited robust cellular and humoral immune responses in
vivo.[9] Upon further investigation, it was found that PPS NPs with carboxylated surfaces
are even more potent activators of complement C3 after serum exposure, eliciting further
amplified immune responses, compared to hydroxylated surfaces.[111]
Altogether, synthetic nano- and micro-particles show much promise as versatile delivery
agents that can finely tune antigen delivery and the activation state of APCs, both in vitro
and in vivo. Particle design and development guided by relatively simple rationales (i.e.
controlling antigen release rate, co-delivery of danger signals) have produced vaccine
particles capable of eliciting very strong humoral and cellular immune responses in small
animal models. However, further detailed studies at the interface of materials science and
immunology will be needed to define the mechanisms underlying these diverse systems and
to permit continued progress driven by rational design rules for augmenting immune
responses.
3.2 Targeting particle vaccines to lymphoid organs
3.2.1 Dendritic cells as live vectors for particle transport—As noted above,
vaccine particles carrying antigens and/or adjuvant molecules can be engineered for efficient
internalization and processing within APCs such as dendritic cells. DCs reside both in
lymph nodes and (in lower numbers) in peripheral tissues. In response to local infection,
peripheral tissue DCs become activated, phagocytose antigen or infected dying cells from
their environment, and migrate to lymphatic vessels, carrying acquired antigen to the
draining lymph nodes (dLNs) to prime naïve T-cells and B-cells.[112] Taking advantage of
this natural trafficking pattern, DC vaccines based on the injection of autologous, ex vivo-
activated and antigen-loaded DCs have been recently commercialized in the first-ever
therapeutic cancer vaccine (for prostate cancer) approved by the FDA.[113] The in vitro
preparation of DCs in this approach provides an ideal opportunity to load these cells with
vaccine particles aimed to optimally promote DC activation and antigen processing. Further,
for clinical assessment and further optimization of this strategy, molecular imaging of
particle-laden DCs has proven to be a valuable tool. Recently, development of
multifunctional Fe3O4-ZnO core-shell NPs was reported, where the iron oxide core served
as an MRI contrast agent and the photoluminescent ZnO shell provided a substrate for
binding tumor antigens fused to ZnO-binding peptides (Fig. 4A).[13] DCs efficiently
internalized these core-shell NPs and were readily visualized in vitro with confocal
microscopy and in vivo with MRI (Fig. 4B). Mice vaccinated with DCs carrying the NP-
tumor antigen complex elicited anti-tumor immunity that significantly suppressed tumor
progression (Fig. 4C). Simultaneous imaging and antigen delivery by loading DCs with
PLGA particles carrying a model antigen, near-infrared fluorophore, and iron oxide NPs has
also been reported.[14] These NP-based strategies for combining antigen delivery with
diagnostic imaging should provide new insights into the functions of DCs in the context of
tumor immunotherapies and normal physiology as well.
3.2.2 Passive targeting of vaccine particles to lymphoid organs—DC vaccines
are a labor-intensive and expensive modality best suited to therapeutic vaccines aimed to
treat life-threatening conditions. For prophylactic vaccines intended for thousands or
millions of people, particle vaccines that can be simply injected into tissues and find their
appropriate targets are needed. There are two routes for “passive targeting” of particles to
lymph nodes from parenteral injection sites (most commonly, the muscle, intradermal, or
subcutaneous (s.c.) tissues): via free diffusion/convection through the tissue to the
lymphatics and then to the draining lymph node (dLN), or via cell-mediated transport as
macrophages or DCs internalize particles at the injection site and actively transport them to
the dLN.[114] Compared to peripheral tissues, lymphoid tissues and organs have a much
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larger population of DCs, the key APC for priming naïve T-cells. Thus, recent work in this
field has sought to optimize particle properties for maximal direct trafficking directly to
LNs.
A critical parameter governing passive targeting is particle size. The extracellular matrix
(ECM) of connective tissues is a meshwork of collagens, elastic fibers, and
glycosaminoglycans, with a heterogeneous porosity that impacts the transport of even
modest-sized macromolecules (albumin, with a hydrodynamic radius of ~3.5 nm, is
excluded from 40–50% of the total volume of interstitial fluid in tissue).[115] Hubbell,
Swartz and colleagues showed that 25 nm diam. pluronic-stabilized polypropylene sulfide
(PPS) NPs were transported to dLNs and acquired by DCs following intradermal injection
much more efficiently than particles of identical composition 100 nm in size (Fig. 5A).[9] In
independent studies, monodisperse, presumably non-stimulatory polystyrene (PS) particles
20 nm in size or virus-like particles ~30 nm in diam. were shown to drain passively to LNs
where they were internalized by LN-resident DCs and macrophages, while larger particles
500–2000 nm in size were primarily transported to dLNs by DC-mediated trafficking.[116]
Thus, particles less than 50 nm in diam. appear to effectively target dLNs by passive
diffusion/convection. However, the fate of submicron particles with diameters ranging from
100 nm to 500 nm after administration seems less clear. Studies of antigen-conjugated PS
particles or viral particles ~200 nm in size have reported accumulation of particles in the
subcapsular sinus of dLNs in a pattern suggesting passive draining following s.c.
injection.[117,118] The discrepancies between these studies of particle size may reflect some
initial impact of mechanical flushing of particles into lymphatics during injection,
differences in particle interactions with the ECM, distinct ECM/lymphatic organization at
different tissue sites used for injection, or other subtle effects of particle composition that are
not yet understood.
Local inflammation in the injection site may also impact particle transport over time.
Substantial lymphangiogenesis has been reported at both the injection site (a near-doubling
of the frequency of lymphatic vessels) and dLNs following immunizations with strong
adjuvants, which alters lymph drainage.[119,120] Nanoparticles have been reported to drain to
the subcapsular sinus of LNs for at least 8 days following s.c. injection,[116] and lymphatic
remodeling in the presence of vaccine adjuvants could sustain or enhance this process.
Antigen-loaded multilamellar lipid vesicles 180 nm in diam. co-injected with the TLR-4
agonist monophosphoryl lipid A were found to accumulate in the subcapsular sinus and
colocalize preferentially with macrophages at 2 weeks following s.c. injection (Fig. 5B).[121]
This result contrasts sharply with the result following injection of the same adjuvant and
antigen mixed in soluble form, where antigen flushed through the lymph node over a period
of a few hours (Fig. 5B).[121,122] Notably, the sustained accumulation of antigen in lymph
nodes following particle immunization in this case correlated with greatly enhanced titers,
avidity, and durability of the resulting antibody response.[121] Thus, clarifying the role of
inflammation in regulating passive and cell-mediated transport of vaccine particles to
lymphoid organs will be important for future studies.
An alternative to passive vaccine particle targeting by diffusion/convection from a
peripheral injection site is to directly administer vaccines into LNs. While impractical for
large-scale prophylactic vaccination, intranodal injections are straightforward outpatient
procedures in humans under ultrasound guidance and have been used in clinical trials of
anti-allergy and cancer vaccinations.[123–125] Two recent studies have illustrated the
potential of intranodal administration to amplify the potency of NP and MP vaccines. When
a series of commonly-studied particulate vaccine carriers, including liposomes, N-trimethyl
chitosan particles, and PLGA MPs, were administered in mice via s.c., intradermal,
intramuscular, or intralymphatic routes, IgG1 antibody responses were all robustly promoted
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independent of the injection site, whereas IgG2a antibody responses depended strongly on
the route of administration.[126] Intralymphatic administration of all 3 particulate vaccine
formulations significantly increased antigen-specific IgG2a antibody titers in sera, and
elicited higher frequencies of IFN-γ-producing splenocytes. These results suggest that
sequestration of large amounts of antigen in LNs by intralymphatic administration may
increase the duration of interaction between antigen and antigen-specific lymphocytes,
promoting “Th1” immune responses that are characterized by elevated IgG2a and IFN-γ
production.[126] Intranodal administration of controlled release particles also enhances the
effectiveness of adjuvant molecules: non-surgical intranodal injection of soluble antigen
mixed with lipid-coated PLGA MPs releasing the TLR-3 agonist polyI:C (Fig. 5C) led to
prolonged polyI:C exposure in the LN, increased adjuvant uptake by DCs in the LNs, and
greatly increased CD8+ T-cell expansion, cytokine production, and antibody responses.[127]
Sustained release of polyI:C into the extracellular LN microenvironment was implicated in
this dramatic enhancement in immune responses, as soluble polyI:C that cleared quickly
from the LN or PLGA NPs that were rapidly phagocytosed in situ failed to elicit similar
responses. Thus, manipulation of the local lymphoid environment via direct injection of
particle vaccines may offer new avenues to maximize delivery of antigen/inflammatory
signals to APCs and induce potent immune responses.
3.2.3 Targeting particle vaccines to dendritic cells with specific ligands and
monoclonal antibodies—Preferential delivery of vaccine particles to APCs can be
achieved by modifying particles with monoclonal antibodies directed against APC-specific
surface receptors. DCs express several C-type lectin receptors, including DEC-205 (CD205),
the mannose receptor (CD206), and DC-SIGN (CD209), which have been implicated as
promising targets due to their physiological roles in antigen uptake.[128] The DEC-205
receptor is selectively expressed by CD8α+ interstitial, lymphoid, and Langerhans DCs,
known for their capacity to cross-present antigens, while CD206 and CD209 are abundant
on DCs and macrophages in the LN medulla.[129] Since antigens fused to anti-DEC-205
antibodies have been shown to undergo cross-presentation in DCs much more efficiently
than antigens fused to either anti-CD206 or anti-CD209,[130] DEC-205 has been the focus of
recent studies to deliver particle vaccines to DCs and promote cellular immune responses.
The first demonstration of using anti-DEC 205 to target vaccine particles to DCs resulted in
~3-fold increases in DC uptake of particles and ~2-fold increases in the magnitude of T-cell
responses in vivo.[131] More recently, DEC-205 targeted, antigen-loaded PLGA NPs were
found to induce secretion of IL-10 and IL-5, Th2-associated cytokines, by DCs and T cells,
and elicited IgG1 antibodies in a DEC-205 density-dependent manner, highlighting the
importance of the surface density of targeting moieties on the outcome of immune
responses.[132] Particle size and antibody-particle linkage chemistry have been shown to be
key factors in the efficacy of targeting particles to DCs.[133,134] When PLGA NPs (200 nm)
and MPs (2 μm) functionalized with humanized DC-SIGN antibody were used to target
human monocyte-derived DCs, the targeting antibody enhanced NP but not MP uptake by
DCs.[133] Particle vaccines can also be targeted to CD206 via its natural carbohydrate
ligand, mannose. Surface-display of mannose increased particle uptake by DCs both in vitro
and in vivo and enhanced expression levels of co-stimulatory markers, inducing antigen-
specific CD4+ and CD8+ T-cell responses.[135–138] A key question for most of these
targeting strategies is whether conjugation of targeting agents to particles too large to freely
diffuse through the extracellular matrix will be capable of achieving substantial targeting,
since particles will only bind DCs they physically encounter and macrophages in the tissue
environment will readily engulf particles in a non-specific manner.
3.2.4 Engineering particle vaccines for mucosal and transcutaneous delivery
—Mucosal tissues, such as the cervicovaginal, respiratory, and gastrointestinal tracts, are the
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most common portals of entry and sites of initial infection for many pathogens, including
HIV, herpes simplex virus, and influenza.[2,139] It is generally observed that protection at
mucosal surfaces against infectious agents is enhanced by vaccines directly applied to these
sites,[140] prompting interest in drug delivery platforms that can deliver vaccines and
therapeutics to mucosal tissues. In addition, mucosal sites such as the airways may be an
attractive target for needle-free vaccines that might be self-administered. However, the
viscous and adhesive mucus layer that lines mucosal surfaces can efficiently trap and rapidly
clear foreign molecules and particles, limiting access of particle vaccines to the underlying
tissue. Thus, recent efforts have focused on developing nanoparticles that can penetrate
mucus layers and deliver cargo materials to the underlining epithelium.
Mucus is a viscoelastic gel that is composed of crosslinked mucin fibers and
proteoglycans.[141] Due to the high negative charge and periodic globular hydrophobic
regions in mucin fibers, mucus can efficiently entrap particles via polyvalent ionic or
hydrophobic interactions. However, an effective strategy to enhance mucus penetration by
particles is to shield particle surfaces with PEG. For example, Hanes and colleagues
demonstrated that PEGylation of hydrophobic poly(sebacic acid) (PSA) NPs increases their
rate of diffusion in human cervicovaginal mucus 250-fold compared to bare particles,
representing a reduction in diffusivity of only 12-fold relative to transport of the particles in
pure water (Fig. 6A).[142] PEGylation with a sufficient density of 2 kDa M.W. PEG chains
allowed particles as large as 500 nm in diam. to penetrate cervicovaginal mucus,[143]
whereas insufficient PEGylation[144] or an increase in PEG MW to 10 kDa[145] resulted in
mucus-adhesive NPs, due to increased interactions between particles and mucin fibers.
These findings were also confirmed in a separate study using PEGylated MPs permeating
through reconstituted mucin hydrogels.[146] Similar strategies have been employed to coat
anionic PLGA NPs with PEG[147,148] or Vitamin E conjugated to 5 kDa PEG as a surfactant,
suggesting the importance of “stealth” layers on particle surface to enhance mucosal particle
delivery.[149] PEGylated PLGA NPs were able to penetrate to the underlining epithelial
tissue after topical intravaginal application, and maintain a high local particle concentration
up to 6 hrs.[148] Besides penetrating mucus, very small PEGylated NPs appear to be
effective in crossing airway epithelial barriers, as 30 nm diam. NPs surface-displaying
antigen administered into the airways with CpG as adjuvant were readily taken up by ~10%
of lung-resident cells, primarily pulmonary macrophages and DCs.[150] APCs with particles
migrated to draining mediastinal LNs and cross-presented the antigen, promoting strong
systemic and local CD8+ T-cell responses that conferred protective immunity against
intranasal flu challenge. Delivery of mucosal vaccines and antiviral therapies may also be
enhanced by achieving efficient encapsulation of vaccine cargo in particles. Saltzman and
colleagues demonstrated that PLGA NPs achieving very high siRNA loading by pre-
complexation of oligonucleotides with spermidine could achieve long-term delivery of
siRNA in the vaginal mucosa.[151] Despite not being particularly engineered for mucus
penetration, these NPs were dispersed throughout vaginal tissues and sustained gene
silencing in areas both proximal and distal to the site of intravaginal application (Fig. 6B).
An alternative to the approach of engineering particles for more efficient penetration of
mucus layers is to develop particles that are adhesive to mucus and/or underlying epithelial
cells to prevent their premature clearance from the mucosal surface. For example, nanogels
composed of pullulan with repeating cholesteryl groups complexed with protein antigen
were recently developed to promote mucosal immunity to tetanus toxoid following
intranasal application.[152] Modification of the nanogels with a cationic polymer backbone
dramatically increased their attachment to the apical membrane of the nasal epithelium via
enhanced ionic interactions with the epithelial cell layer (Fig. 6C). These cationic particles
acted as an artificial chaperone and remained adhered mostly on the epithelium surface
while releasing antigen to the underlining tissues, where > 40% of DCs in the local tissue
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internalized the antigen and elicited strong immune responses. Antigen-loaded hydrophobic
polyanhydride nanoparticles, which might act in a similar manner by binding to mucus via
the hydrophobic domains of mucins, were recently shown to promote robust protection of
mice against challenge with the plague bacterium Yersinia pestis following intranasal
vaccination.[153] Intranasal and pulmonary administration of polyelectrolyte
microcapsules[154] and liposomes[155] have also been demonstrated to target antigen to
alveolar DCs and macrophages. Finally, another route of administration currently being
examined for mucosal immunity is oral vaccination. The fate of anionic polylactide vaccine
particles with 200 nm diameter has been tracked using a murine ligated ileal loop and an
oral gavage model.[156] Particles initially entrapped in the mucus eventually crossed the
epithelial barrier through M-cells, and accumulated in the Peyer’s patches, where local B
cells and DCs interacted with the particles. These results indicate that particulate
formulations may offer a versatile delivery platform for mucosal vaccines.
4. Modifying immune reactions in tumors
The immune system exerts both beneficial and detrimental effects on tumor growth during
all stages of cancer. In animal models, natural killer cells and CD8+ T-cells have been
shown to remove stressed or damaged cells that may become cancerous, and are especially
crucial in preventing carcinomas caused by infectious agents such as human papilloma
virus-induced cervical cancer. Cancer immunotherapy, the design of treatments directing the
immune system to attack tumors, is gaining increasing interest with recent successes in the
licensure of the first therapeutic cancer vaccine[157] and approval of an anti-CTLA-4
antibody that promotes anti-tumor immune responses.[158] Particles designed to deploy
immunomodulatory drugs in the tumor environment or systemic lymphoid compartments
may provide an important tool for further enhancing antitumor immunity. In addition,
strategies leveraging immune cells themselves as delivery vehicles for active targeting of
cancer therapeutics to the tumor microenvironment have recently been demonstrated.
4.1 Targeting immunomodulators to tumors with nanoparticles
While progressing primary tumors are often infiltrated by immune cells, these populations
are often enriched in myeloid-derived suppressor cells, regulatory T cells, tumor-associated
macrophages and other immunosuppressive cells actively recruited and co-opted by the
tumor.[159] These co-opted cells secrete factors that fuel tumor growth and metastasis, as
well as render tumor-infiltrating T cells ineffective or apoptotic. The genetic heterogeneity
of tumors and their exploitation of multiple, redundant signaling pathways to block immune
responses suggests that targeting single suppressive pathways will be unlikely to have major
therapeutic benefit. Rather, strategies to reverse tumor immunosuppression will need to
target “master” immune regulators that govern multiple pathways simultaneously. One
promising target for immunosuppression blockade is the transcription factor STAT3, which
is expressed by a high frequency of human cancers as well as tumor-associated stromal
cells.[160,161] Constitutively active STAT3 in myeloid cells induces secretion of
immunosuppressive factors and inhibits production of Th1 cytokines that are essential for
anti-cancer immune responses. Thus, therapies aimed to silence STAT3 expression in either
tumor or stromal cells may provide beneficial immune responses in the tumor
microenvironment. NPs composed of PLGA directly conjugated with JSI-124, a small
molecule inhibitor of STAT3, exhibited sustained drug release over one month, and
suppressed activation of STAT3 in DCs, while promoting T cell proliferation in a mixed
lymphocyte assay in vitro.[162] In addition to small-molecule drugs, siRNA, which has
recently emerged as a powerful therapeutic modality for specific and effective
downregulation of protein expression, can be delivered via NPs in a targeted manner and
mediate profound immunomodulation in the tumor microenvironment. Modification of
polyethylenimine (PEI) with stearic acid increased siRNA condensation and protected
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siRNA against degradation in serum.[163] STAT3 siRNA complexed with stearate-modified
PEI reduced the expression level of activated STAT3 in B16 melanoma cells and
significantly suppressed tumor growth in vivo, by inducing IL-6 production and Caspase 3
activity, while diminishing VEGF secretion in tumors.[163] Toxicity associated with the
cationic PEI was subsequently addressed by the same group, who have demonstrated that
incorporation of siRNA-PEI polyplexes in PLGA NPs reduces the nonspecific toxicity
profile of the polyplexes while maintaining the gene knockdown efficiency by siRNA in
DCs (Fig. 7A).[164] Notably, treatment of tumor-tolerized DCs with these NPs blocked
STAT3 activation in the cells and restored their function, as evidenced by increased TNF-α
secretion and T cell priming (Fig. 7B). When combined with cancer vaccines, suppression-
blocking therapies can also synergistically enhance anti-cancer immune responses and
suppress tumor growth, as demonstrated in a murine model of breast cancer with anti-
HER-2 DNA vaccine and NPs carrying a chemical inhibitor of STAT3.[165] Thus
nanoparticles can be effective for targeting immunomodulatory drugs to multiple cell types
within tumors.
A major challenge in immunotherapy is the high systemic toxicity often elicited by
immunostimulatory cytokines or antibodies.[166] Local immunostimulation in the tumor
microenvironment may provide a strategy to avoid such systemic toxicity, and it has been
proposed that local treatments amplifying anti-tumor immunity at one tumor lesion may be
capable of turning a tumor into its own vaccine, unleashing a systemic immune response that
could lead to eradication of distant (untreated) metastases.[167–170] Micro- and nano-
particles may be very useful in this context for confining strong stimulatory signals to the
tumor or tumor-draining lymph nodes. For example, agonistic antibodies against the
costimulatory receptor CD40 expressed by DCs and macrophages can elicit potent anti-
tumor immune responses, but systemic administration of anti-CD40 elicits dose-limiting
hepatic toxicity and systemic inflammatory effects, which have limited its clinical
translation.[171–174] To address this issue, a liposome-based drug delivery platform was used
to localize delivery of anti-CD40 and TLR agonists in the tumor microenvironment.[175]
Liposome-anchored anti-CD40 and CpG oligonucleotides were synthesized by direct
conjugation of anti-CD40 to PEGylated vesicles via maleimide-thiol reaction, followed by
post-insertion of lipid-conjugated CpG (Fig. 7C). Liposomes bearing anti-CD40 and CpG on
their surfaces suppressed tumor growth in the aggressive, poorly immunogenic B16F10
murine model of melanoma, and delayed tumor progression better than equivalent doses of
soluble agonists when injected intratumorally (Fig. 7D). Importantly, unlike soluble
antibody or oligos, anti-CD40/CpG anchored on liposomes sequestered these agonists within
the tumors and tumor-draining lymph nodes after intratumoral administration. Blockade of
drug leakage into the circulation eliminated systemic toxicities associated with these agents,
including liver damage, weight loss, and systemic release of inflammatory cytokines (Fig.
7E, F). Thus, nanoparticles can enhance the efficacy of immunotherapy molecules by
regulating their biodistribution.
4.2 Targeting tumors with particle-carrying leukocytes
A chaotic vasculature, high interstitial pressure and dense extracellular matrix can prevent
efficient extravasation and diffusion of systemically-administered therapeutic particles into
tumors.[176] Leukocytes overcome this transport obstacle by recognizing molecular markers
of inflammation found on tumor vasculature and actively transmigrating into the tumor bulk.
Taking advantage of this intrinsic trafficking behavior, strategies have been recently
reported to functionalize live cells with synthetic materials and therapeutic molecules, which
are then shuttled into tumors following adoptive cell transfer. This approach can be used to
deliver drugs that act on the tumor, stroma, or the functionalized carrier cells themselves.
For example, in a two-step pre-targeting strategy, macrophages “fed” gold nanoshells were
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shown to infiltrate in vitro human breast carcinoma tumor spheroids, including the hypoxic
necrotic center– a site devoid of functional vasculature that by definition cannot be
effectively targeted by “free” nanoparticles administered systemically (Fig. 8A, B).[177]
Irradiation with near-infrared light rapidly heated the engulfed silica-gold nanoshells and
caused death of the carrier macrophages as well as bystander tumor cells. This “Trojan
horse” approach is interesting not only as a strategy to directly kill tumor cells but also
because macrophages that home to tumors are often co-opted by the tumor
microenvironment to provide cytokines promoting tumor progression,[178] and thus their
simultaneous ablation during irradiation may reinforce the anti-tumor effect of this therapy.
In a similar vein, gold NPs were shown to be internalized by human T cells without
impairing in vivo tissue homing, and increased NP accumulation in tumors by several fold in
a xenograft model of lymphoma, compared to free particle injection (Fig. 8C).[179] Another
approach is to rely on direct surface conjugation of tumoricidal NPs to tumor-infiltrating
cells. As a conceptual demonstration, human mesenchymal stem cells (which can exhibit
tumor tropism) were conjugated with polystyrene NPs via a biotin-streptavidin bridge.[180]
These stem cells retained their NPs for up to two days and retained their ability to orient
towards tumor spheroids in vitro. This strategy is generalizable to virtually any combination
of tumor-infiltrating cells and therapeutic NPs, and may allow access to tumors deep in the
tissue that are not easily penetrated by irradiation.
As described in section 2.1, ex vivo-expanded tumor-reactive T-cells are being used to treat
metastatic cancer in adoptive cell therapy. Maintenance of the anti-tumor activity of T-cells
following infusion of the cells into patients is typically achieved by the systemic
administration of adjuvant drugs such as interleukin-2, which stimulate T-cell survival and
effector functions.[25] However, such adjuvant drug treatments have significant toxicities
that limit their efficacy. As one strategy to overcome this limitation, nanoparticles loaded
with adjuvant cytokines were chemically conjugated to the surface of T-cells, enabling tiny
doses of adjuvant drugs to be very efficiently provided to their parent lymphocyte while
avoiding unwanted systemic exposure to these potent molecules.[17] Key to this approach is
stable cell surface binding, so that cytokine cargo released from the nanoparticle can bind to
cell surface receptors; internalization of the particle would physically prevent protein drug
cargos from accessing their target receptors on the carrier cell.[181] Typically, specific
binding to target cells is achieved by functionalizing particles with ligands which will bind
to molecules expressed on the surface of the target cell, but often, ligand binding to proteins
on the cell surface will trigger endocytosis of the particle.[27,182,183] However, by
crosslinking nanocarriers to T-cells via thiol-reactive maleimide groups that conjugate to
multiple cell surface proteins, lipid or polymer nanoparticles loaded with protein drugs could
be stably attached to the surfaces of T-cells for up to a week, even during cell division (Fig.
8D, E).[17] T-cells thus decorated with cytokine-releasing nanoparticles carried nanoparticles
into tumors, at levels greatly exceeding particle entry into tumor sites by passive diffusion/
convection from the blood (Fig. 8F). These particle-decorated T-cells exhibited greatly
enhanced proliferation in vivo compared to T-cells supported by equivalent doses of
systemically-administered cytokine, leading to dramatic elimination of established tumors in
mouse models of melanoma.[17] Thus, cell engineering with synthetic particles is a potent
strategy for enhancing tumor therapy, and might be of interest in other settings of cell
transplantation.
5. Nanoparticles for systemic delivery of antiviral, anti-inflammatory, and
autoimmune therapies
In addition to vaccine delivery and tumor therapy, tailored nanoparticles are being explored
in several additional contexts for treating infectious disease and autoimmunity. We will
confine our discussion here to the use of particles to target drugs to immune cells or infected
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host cells, and note that a large body of literature has also explored the use of nanoparticles
as materials to target therapeutics that act directly on microbes, such as antimicrobial
peptides and polymers, a topic outside the scope of this Progress article that has been
reviewed elsewhere recently.[184–186] We will also discuss exciting recent studies exploring
unexpected novel effects of lymphocyte-targeted nanoparticles in autoimmunity.
5.1 Targeting infections with nanoparticles
The blood-brain barrier (BBB) is a major obstacle in drug delivery to the brain and severely
limits our ability to treat many diseases affecting the central nervous system (CNS),
including HIV, glioma, and Alzheimer’s disease. Targeted delivery of NPs carrying drugs to
brain capillary endothelial cells, neurons, and the brain parenchyma have been recently
demonstrated using various targeting moieties, including apolipoprotein E,[187]
angiopep-2,[188] lactoferrin,[189] sialic acid residues,[190] and trans-activating transcriptor
(TAT) peptides[191] with varying delivery efficiencies and therapeutic successes. To address
variable BBB penetration by macromolecules or targeted NPs encapsulating drugs, a new
strategy based on cell-based targeted delivery to the brain has been recently
demonstrated.[18,192] In a murine model of a HIV-1 encephalitis, Gendelman and colleagues
administered macrophages that were pre-incubated with NPs encapsulating the retroviral
drug indinavir. The particle-pulsed macrophages crossed the BBB and shuttled the drug to
HIV-infected subcortex regions, sustaining increased local drug concentration for 14 days
and suppressing HIV-1 replication, in comparison to i.v. administration of the drug (Fig.
9).[18,192]
Systemic injection of particles loaded with antiviral drugs may deplete viral reservoirs in
infected patients, providing a therapeutic means to control infection. Taking this approach
one step further, Shankar and colleagues aimed to “vaccinate” mice against infection using
particles loaded with siRNA to downregulate CCR5, a key receptor required for R5-tropic
HIV strains to infect immune cells.[193] In a humanized mouse model of HIV, systemic
administration of siRNA-loaded liposomes targeted to leukocytes via an antibody against the
integrin lymphocyte function-associated antigen-1 silenced CCR5 expression in vivo for 10
days, and enhanced resistance to HIV infection as evidenced by reduction in plasma viral
load and CD4 T-cell loss. Together, these studies demonstrate that NPs carrying antiviral
agents can be delivered to desired tissue targets to control infection in both prophylactic and
therapeutic settings.
5.2 Nanoparticle modulation of the innate immune system in autoimmune diseases
Autoimmune diseases are often accompanied by chronic inflammation that fails to resolve
and contributes to tissue damage. Thus, strategies to deliver anti-inflammatory drugs
selectively to innate immune cells in inflamed tissues and reverse their pathological
phenotypes are of great interest in treatments against autoimmune diseases. Recently,
nanoparticle-based platforms, such as liposomes and dendrimers, have been utilized as drug
delivery carriers for small molecule anti-inflammatory agents[194,195], plasmids encoding for
immunomodulatory proteins (OX40-TRAIL)[196], or peptide antigens[197] to suppress
production of inflammatory cytokines and ameliorate clinical symptoms in animal models of
rheumatoid arthritis and multiple sclerosis (experimental autoimmune encephalomyelitis).
Moreover, it has been recently shown that drug-conjugated dendrimers with dual anti-
inflammatory and anti-osteoclastic properties can relieve symptoms of rheumatoid arthritis
without further exogenous biological or chemical agents.[198] Whereas conventional
monoclonal antibodies or soluble cytokine receptors solely target inflammatory cytokines,
dendrimers capped with azabisphosphonate were able to inhibit the secretion of pro-
inflammatory cytokines by inflammatory monocytes and simultaneously block a signaling
pathway essential for their differentiation into osteoclasts, thereby achieving a two-pronged
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approach to inhibit inflammation and bone-resorption in two murine models of rheumatoid
arthritis. Such strategies to develop therapies based on the innate biochemical properties of
polymers on target immune cells should be investigated further toward the development of a
clinical therapy against autoimmune diseases.
Several of the targeting strategies based on the intrinsic trafficking of nanoparticles or
cellular chaperones discussed earlier have also been used to treat autoimmune and
inflammatory conditions. For example, nanoparticle drug carriers administered
intravenously will often accumulate preferentially in the spleen and bone marrow (in
addition to the liver). Exploiting this innate tropism of NPs, siRNA was targeted to
inflammatory monocytes in the spleen and bone marrow to suppress expression of the
chemokine receptor CCR2.[199] Downregulation of CCR2 in monocytes with siRNA-NP
therapy prevented accumulation of inflammatory monocytes and their differentiation into
highly activated antigen-presenting macrophages at the sites of inflammation. Impressively,
this single therapeutic approach reduced inflammation in atherosclerotic plaques, decreased
infarct size after coronary artery occlusion, prolonged survival of pancreatic islet allografts
after transplantation, and suppressed tumor growth.[199] Lastly, the tropism of DCs for
lymph nodes as discussed earlier has been exploited to shuttle immunosuppressive drugs to
lymphoid tissues in a selective manner.[200] DCs were incubated with NPs pre-loaded with
cyclosporine-A, an immunosuppressive agent, and when infused back into animals, NP-
carrying DCs migrated to draining lymph nodes, successfully suppressing proliferation of T-
cells in the local lymphoid tissue without any significant systemic release of the toxic drug.
5.3 Nanoparticles as targeted therapies in autoimmunity
T-cells are critical effectors that play an important role in protecting the host via their ability
to eliminate infected cells or destroy tumor cells, but they can also directly cause tissue
damage in autoimmune diseases like type 1 diabetes and multiple sclerosis. Thus, strategies
to inhibit T-cell functions are also of great interest. One strategy to suppress autoimmune
reactions is to redirect the program of inflammatory T-cells. CD4+ “helper” T-cells
differentiate into subclasses that serve different functions in regulating immune responses–
Th1 cells that help clear intracellular pathogens, Th2 and Th17 cells that deal with
extracellular parasites, and Treg cells (regulatory T-cells) that suppress the effector
functions of other T-cells. Th1, Th2, and Th17 cells have all been implicated in different
autoimmune diseases. Importantly, it is now known that CD4+ T-cells have the capacity to
interconvert between these different effector programs in response to different cytokine
cues.[201] This raises the possibility of using drug treatment to convert (for example)
disease-causing inflammatory Th17 T-cells into regulatory T-cells, simultaneously blocking
the unwanted function of the Th17 cell and introducing a new regulatory cell that may block
the inflammatory activity of other effector T-cells in the tissue environment. Nanoparticles
offer the possibility to target such identity-altering drugs to T-cell populations. For example,
anti-CD4-targeted PLGA NPs loaded with leukemia inhibitory factor, a tolerogenic
cytokine, were shown to expand Foxp3+CD4+ Tregs and prolonged survival of heart
allografts between mismatched donor-recipient model in vivo.[202] In contrast, NPs loaded
with IL-6 exerted the opposite effect, promoting CD4+ Th17 cell development.
A key objective in treating autoimmune disease is the ability to selectively turn off only
those T-cells attacking healthy tissue, in order to avoid generalized immunosuppression that
cause lead to opportunistic infections. Because the antigen specificity of T-cells is
determined solely by each cell’s unique T-cell receptor (TCR), targeting of disease-specific
cells has been achieved by using self-antigen peptide-MHC (pMHC) complexes as disease-
specific ligands that will bind the TCR of autoreactive T-cells. Notably, the low affinity of
TCRs for pMHC (KD values typically ~1–10 μM), means that multivalent display of pMHC
from the surface of nanoparticles is an effective strategy to obtain high avidity, specific
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binding to target T-cells.[203] Amphiphilic dendrimers with a hydrophobic core and PEG
corona coupled to specific pMHC ligands have been used to deliver the DNA-binding toxin
doxorubicin (sequestered in the dendrimer core) to antigen-specific T-cells, showing
suppression of T-cell proliferation in vitro and in vivo.[203] More recently, it has been shown
that pMHC ligands can themselves serve as both a targeting agent and the effector molecule
to suppress autoreactive T-cells. This approach is based on the concept that naïve T-cells
that are triggered through their TCR in the absence of costimulation (critical accessory
signals normally provided in parallel by APCs) will be driven to undergo apoptosis or
become anergic, i.e. unresponsive to antigen. Such tolerizing signals could in theory be
provided by monomeric pMHC, but multivalent display of pMHC ligands on nanoparticles
overcomes the low affinity of individual ligands for binding to target cells and may enhance
delivery of tolerizing signals to the TCR by virtue of promoting TCR clustering on binding
to the T-cell.[204] Santamaria and colleagues tested this concept and discovered that systemic
injections of pMHC-conjugated iron oxide NPs could protect mice from autoimmune
diabetes, but that rather than anergizing or deleting naïve disease-specific T-cells, the pMHC
NPs induced expansion of pre-existing “autoregulatory” memory CD8+ T-cells in vivo.[205]
These memory cells were naturally produced in diabetic mice as a regulatory response by
the immune system seeking to control the autoimmune reaction; injection of pMHC NPs
specific for a target diabetes antigen triggered the expansion of these regulatory T-cells,
which were then capable of suppressing the autoimmune attack on pancreatic islet cells,
essentially providing a boost to the immune systems’ own efforts to control the autoimmune
disease. An important strength of this approach is that injection of NPs carrying a single
type of pMHC (i.e. targeting T-cells reactive to only one disease-related peptide) led to
suppression of autoimmune responses against multiple diabetes antigens– meaning that
suppression of autoreactivity does not require a different NP for each potential disease
antigen. This is critical for a broadly applicable strategy that could be used in the diverse
human population (where treatments might need to account for the >2,000 different known
MHC molecules in humans) and because the complete profile of autoimmune antigens
involved in type 1 diabetes remain unknown. These examples illustrate the power of
nanoparticle therapeutics to not only achieve therapeutic success but to also reveal important
new aspects of immune physiology regulating disease states.
6. Conclusions and future outlook
Recent progress in the synthesis of multifunctional biodegradable/biocompatible particles
has provided new momentum to translate discoveries from basic immunology into novel
therapies and diagnostics for numerous diseases, including cancer, infectious diseases, and
autoimmunity. As illustrated by the diverse examples discussed here, novel engineered
nano-and micro-particles are showing promise as potent adjuvants for vaccines,[9,10,127,152]
drug carriers for cancer immunotherapy,[164,175] and as systemic delivery vehicles with
circulation times in excess of a week in vivo.[68,69]. In parallel with advances in particle
design and synthesis, important new ways of using engineered particles are coming to light,
such as using living cells as Trojan horse chaperones to carry drug-releasing particles into
target tissues[18,177] or employing nanoparticles as cell surface modification reagents for cell
therapies.[17,180] However, this rapidly moving field is still very young and these early
advances also suggest additional new avenues that may be important areas of study in the
coming few years.
One avenue ripe for investigation lies at the intersection of advances in the design of long-
circulating particles and the design of particle vaccines. Vaccines are traditionally
administered by parenteral injection at one or (at most) a few sites, meaning that often only a
single lymph node may be involved in priming of adaptive immune responses. This is in
contrast to infectious agents, which may systemically disseminate and elicit extremely
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potent immune responses by involving many lymph nodes, Peyer’s patches in the gut, and/or
the spleen. Particles engineered to avoid rapid RES clearance which could release vaccine
components systemically might provide a route to “systemic immunizations” that could
recruit a large number of lymphoid organs into the immune response with a single injection.
Further, future studies providing targeting abilities to long-circulating nano- and micro-
particles by displaying monoclonal antibodies or other targeting agents could be used to
preferentially target critical antigen presenting cells residing in the spleen, lymph nodes, and
bone marrow, while avoiding clearance by the liver. Another parallel question is whether
strategies to avoid particle uptake by the RES after systemic administration may be similarly
applied to maximize delivery of particles to lymph nodes after parenteral administration.
Thus, more studies are warranted to explore the impact of particle shape and modulus
delineating the tissue draining patterns of particles and their impact on the immune system.
A second key challenge will be to build on recent strategies of using particles to target drugs
or imaging agents to specific immune cells[202,205] or tissues,[9,127] with the goal of
systemically modulating the immune system. Leukocytes are attractive targets for targeted
particle therapies as they are present at very high concentrations in lymphoid organs that can
be accessed by nonsurgical injections, and unlike parenchymal cells of many tissues, they
recirculate through the blood. The clinical success of monoclonal antibodies targeting
leukocyte-derived cancers is mediated in large part by the ready access of these therapeutics
to isolated target cells in the blood (which can be contrasted by the poor ability of antibodies
or nanoparticles to penetrate solid tumors). Antibody- or ligand-targeted particles should be
capable of delivering immunomodulatory drugs to a majority of target immune cells,
especially if particle properties are optimized to provide sufficient circulation half-life to
these carriers, enabling either amplification or suppression of specific immune responses.
Strategies to target antigen-specific disease-associated leukocytes (e.g., antigen-specific T-
cells or B-cells) without triggering negative regulatory or suppressive signals in these cells
will be an important challenge to overcome, as the only unique cell surface marker
expressed by these cells is their antigen receptor, and as discussed above, nanoparticles that
are best suited by virtue of their size for systemic targeting have been found to trigger
anergy or regulatory differentiation when decorated with specific antigens that bind to T-cell
receptors[205] (a boon for antigen-specific treatments for autoimmunity, but a bane for
treatments aiming to bolster immunity).
Altogether, the significant progress made over the past few years at this exciting interface of
immunology and materials science strongly suggests that nano- and micro-particles will
provide new, effective means to treat and diagnose various diseases in the near future.
Tackling these challenges will require continued innovation in materials design, with an
increasing focus on problem-specific needs of individual diseases.
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EC endothelial cells
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Figure 1. Engineered particles as synthetic antigen presenting cells
(A) Schematic view of key receptor-ligand interactions at the immunological synapse
formed between an antigen presenting cell (APC, such as a dendritic cell) and a T-cell
during T-cell activation. (B) Upper panel, schematic view of microparticles engineered as
artificial APCs (aAPCs), which display ligands and release cytokines to stimulate T-cells.
Lower panel, confocal microscopy view of immunological synapse formed between aAPC
microparticle (red) and several T-cells (nuclei, blue; actin, green). (C) Fabrication of
anisotropic “patchy” protein-coated microparticles by (i) forming colloidal crystals of
microparticles, (ii) applying polydimethylsiloxane as a masking agent, (iii) PDMS masking
at particle contact points, (iv) separation of particles from the scaffold, and finally (iv) two-
step protein coating. Lower right, confocal micrograph illustrates dual protein patterning on
patchy microspheres. Panel (B) reproduced with permission from [16]. Copyright 2008,
Nature Publishing Group. Panel (C) reproduced with from [38]. Copyright 2011, Wiley.
Moon et al. Page 30
Adv Mater. Author manuscript; available in PMC 2013 September 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Modulation of particle interaction with phagocytes
(A) The effect of the contact angle between particles and cell membranes on the rate of
particle internalization, demonstrating poor phagocytosis of highly anisotropic particles. (B)
A flow chamber assay demonstrating rapid uptake of small, isotropic micelles by
macrophages, but minimal uptake for long, flexible filomicelles. Scale bars, 5 μm. Panel (A)
reproduced with permission from [47]. Panel (B) reproduced with permission from [69].
Copyright 2007, Nature Publishing Group.
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Figure 3. Active targeting of lymphoid organs with particle-carrying leukocytes
(A) Left panel, schematic of layer-by-layer capsule assembly by (i, ii) incubating a colloidal
template with antigen, (iii, iv) alternate deposition of interacting polymers to form (v) a
multilayered structure, followed by (vi) dissolution of core template. Right panel, confocal
image of capsules (green) internalized into dendritic cells (membrane in red and nuclei in
blue). (B) Upper panel, confocal images of untreated DCs, and DCs loaded with αAl2O3
NPs (green) and stained with antibody against the autophagosome marker, LC3 (red). Lower
panel, TEM images showing that internalized αAl2O3 NPs are located inside endosomes/
phagosomes, autophagosomes, and autolysosomes of DCs. Panel (A) reproduced with
permission from [81]. Copyright 2008, Wiley. Panel (B) reproduced with permission
from [61]. Copyright 2011, Nature Publishing Group.
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Figure 4. Active targeting of lymphoid organs with particle-carrying leukocytes
(A) Schematic illustration of Fe3O4-ZnO core-shell nanoparticles coated with tumor
antigens fused to ZnO-binding peptides. (B) In vivo MRI image showing accumulation of
dendritic cells labeled with nanoparticles in draining lymph nodes. (C) Enhanced
suppression of tumor growth after injection of dendritic cells carrying tumor antigen-loaded
iron oxide NPs (open red squares) compared to administration with antigen only (open blue
triangles), DCs only (filled black circles), or NPs (open black circles). Reproduced with
permission from [13]. Copyright 2011, Nature Publishing Group.
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Figure 5. Delivery of vaccine particles to lymphoid organs
(A) Direct draining of sub-50 nm nanoparticles to lymph nodes from s.c. injection sites.
Upper panel, histological sections of draining lymph nodes 1 day after administration of
poly(propylene sulfide) NPs (red) with mean diameters of 100 nm or 25 nm. Scale bar, 200
μm. Lower panel, percentage of dendritic cells that internalized PPS NPs in the lymph node.
(B) Histological section of draining lymph nodes over time after s.c. injection of either
soluble antigen (ovalbumin, shown in red) or antigen encapsulated in180 nm diam.
multilamellar lipid nanoparticles (blue). Germinal centers in the LN detected by staining
with GL-7 antibody on day 14 are shown in green. Scale bar, 10 μm. (C) Intranodal
administration of fluorescent PLGA microparticles detected by whole-animal fluorescence
imaging (upper panels) or imaging of excised intact lymph nodes (lower panels). (D)
Histological section of lymph node following direct intranodal injection of fluorescent
PLGA particles (green) with staining for markers of B-cells (B220, blue) and T-cells (CD3,
red). Panel (A) reproduced with permission from [9]. Copyright 2007, Nature Publishing
Group. Panel (B) reproduced with permission from [121]. Panel (C) reproduced with
permission from [127]. Panel (D), courtesy of C.M. Jewell, S.C. Bustamante López, and D.J.
Irvine.
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Figure 6. Particles designed to penetrate mucosal barriers
(A) Improved mucus-penetrating ability of poly(sebacic acid) (PSA) NPs after PEGylation
as evidenced by increase in effective diffusivity and fraction of particles penetrating human
cervicovaginal mucus. (B) Fluorescence image of reproductive tract on day 1 after
intravaginal administration of siRNA-loaded PLGA NPs. (C) Mucus-binding particles for
intranasal vaccine delivery. Upper panel, wide distribution and attachment of antigen-loaded
nanogels on nasal epithelium after intransal administration. Scale bar, 500 um. Lower panel,
release and transport of antigen (green) from nanogels (red) into the epithelial layer over
time. Scale bar, 20 um. Panel (A) reproduced with permission from [142]. Panel (B)
reproduced with permission from [151]. Copyright 2009, Nature Publishing Group. Panel (C)
reproduced with permission from [152]. Copyright 2010, Nature Publishing Group.
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Figure 7. Nanoparitcle delivery of immunomodulatory drugs in tumors
(A, B) Encapsulation of STAT3-sirNA/PEI polyplexes in PLGA nanoparticles to reduce
cytotoxicity while maintaining gene silencing activity. (A) Schematic view of polyplex
encapsulation. (B) Kockdown of STAT3 in dendritic cells by encapsulated polyplexes,
compared to controls with scrambled siRNA (sc) or naked siRNA. (C–F) Blockade of
systemic side effects by anchoring immunostimulatory ligands to lipid vesicles for
intratumoral injection. (C) PEGylated liposomes displaying aCD40 and CpG were
synthesized by surface-conjugation of anti-CD40, followed by post-insertion of CpG-lipid
conjugates into the outer leaflet of the vesicle bilayer. Suppression of tumor growth (D)
without weight loss (E), liver damage (not shown), or systemic cytokine release (F) after
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intratumoral injection of liposomes displaying anti-CD40 and CpG, compared to equal doses
of soluble ligands. Panels (A, B) reproduced with permission from [164]. Copyright 2010,
American Chemical Society. Panel (C–E) reproduced with permission from [175]. Copyright
2011, Elsevier.
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Figure 8. Leukocyte-mediated delivery of nanoparticles to tumors
(A, B) Gold nanoshells transported into tumors by macrophages for photothermal therapy.
(A) TEM micrographs of a gold nanoshell-laden macrophage (upper panel) and monocytes
(lower panel). Higher magnification views at right show aggregates of nanoshells inside the
cells. (B) Histological tissue section of T47D tumor spheroid showing infiltrating nanoshell-
laden macrophages (black) within the viable tumor as well as near areas of necrosis (pink
staining; white arrow). (C) T-cells can carry internalized gold nanoparticles into tumors.
Resected subcutaneous LCL xenograft tumors were analyzed by bright field imaging (top
row) and immunohistochemistry for human CD3 expression and dark field imaging (bottom
row) to indicate the presence of gold NPs. Red arrows indicate the colocalization of CD3+ T
cells and AuNPs within the tumor. (D–F) T-cells carry surface-bound nanoparticles into
tumors in vivo. (D) Lipid nanoparticles were stably conjugated to the surfaces of T-cells via
maleimide-thiol reaction. (E) Nanoparticles remained on the surfaces of T-cells after 4 days
of stimulation in vitro. (F) TRAMP mice bearing spontaneous prostate tumors were injected
with fluorescent lipid NPs alone, Luciferase-expressing tumor-targeting T-cells alone, or
luc-expressing T-cells carrying surface-bound NPs. Upper panels, whole-animal
bioluminescence imaging of T-cell trafficking to the prostate tumors (dashed circles). Lower
panels, fluorescence imaging of dissected intact prostates showing that free NPs achieve no
entry into tumor site, while T-cells carry substantial quantities of particles into the tumor.
Panels (A,B) reproduced with permission from [177]. Copyright 2007, American Chemical
Society. Panel (C) reproduced with permission from [179]. Panel (D,E) reproduced with
permission from [17]. Copyright 2010, Nature Publishing group. Panel (F), courtesy of M.
Stephan, E. Higham, K.D. Wittrup, and J. Chen.
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Figure 9. Crossing blood-brain-barrier with particle-carrying leukocytes
Bone marrow macrophages (BMM) loaded with drug-carrying nanoparticles have been used
to treat HIV-1 infection in the brain. (Left panels) Histological images demonstrating
migration of macrophages loaded with iron oxide NPs (blue staining) into
neuroinflammatory HIV-1-infected brain sites (upper panels), but not control brain sections
(lower panels). Right panels, dramatic reduction in HIV-1 infected brain sites (detected by
staining for HIV p24 protein, blue) after treatment with macrophages carrying NPs loaded
with anti-retroviral drugs. Reproduced with permission from [18]. Copyright 2009, American
Association of Immunologists.
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